Dimension Therapeutics (NASDAQ:DMTX) Getting Somewhat Positive News Coverage, Study Finds

News headlines about Dimension Therapeutics (NASDAQ:DMTX) have trended somewhat positive this week, Accern reports. The research group identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Dimension Therapeutics earned a coverage optimism score of 0.06 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 47.0568200376826 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Dimension Therapeutics (NASDAQ DMTX) traded up 6.12% on Friday, reaching $1.30. The company had a trading volume of 31,260 shares. Dimension Therapeutics has a 52 week low of $1.05 and a 52 week high of $9.98. The company’s market capitalization is $32.57 million. The stock’s 50-day moving average is $1.33 and its 200-day moving average is $1.50.

Dimension Therapeutics (NASDAQ:DMTX) last issued its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.49). The business had revenue of $4.37 million for the quarter. Dimension Therapeutics had a negative return on equity of 98.72% and a negative net margin of 358.21%. Equities research analysts forecast that Dimension Therapeutics will post ($1.99) EPS for the current fiscal year.

Several research analysts have recently issued reports on the company. Chardan Capital reissued a “hold” rating on shares of Dimension Therapeutics in a research report on Monday, August 14th. Zacks Investment Research lowered Dimension Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, July 10th. Canaccord Genuity reduced their price objective on Dimension Therapeutics from $20.00 to $12.00 and set a “buy” rating for the company in a research report on Wednesday, June 28th. Cantor Fitzgerald set a $3.00 price objective on Dimension Therapeutics and gave the company a “hold” rating in a research report on Saturday, June 10th. Finally, Citigroup Inc. lowered Dimension Therapeutics from a “buy” rating to a “neutral” rating and set a $1.50 price objective for the company. in a research report on Friday, May 12th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $5.88.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this piece can be viewed at https://www.com-unik.info/2017/08/19/dimension-therapeutics-nasdaqdmtx-receiving-somewhat-favorable-news-coverage-accern-reports-updated.html.

About Dimension Therapeutics

Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).

Insider Buying and Selling by Quarter for Dimension Therapeutics (NASDAQ:DMTX)

What are top analysts saying about Dimension Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Dimension Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit